Blood test can be used to identify the presence of a protein that can reveal underlying neurodegeneration
News
SMC backs five new medicines for NHS use
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
NICE recommends Tecentriq for first-line NSCLC
Tecentriq is indicated for adults with metastatic NSCLC if their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells
Biogen, Eisai’s Alzheimer’s drug aducanumab makes history with US approval
First new treatment approved for Alzheimer’s disease in over a decade
Tickets now on sale for INTCR 2021
Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards.
Amgen’s KRAS inhibitor Lumakras scores positive overall survival data
Lumakras showed a median overall survival of 12.5 months in previously treated NSCLC patients
GSK’s PD-1 inhibitor Jemperli approved in the UK
Conditional marketing authorisation granted for the treatment of recurrent or advanced endometrial cancer
Iksuda Therapeutics raises $47m to progress ADC pipeline
Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase I clinical trials
MHRA authorises Pfizer/BioNTech’s COVID-19 vaccine for 12- to 15-year-olds
JCVI will advise on whether this younger age group will be vaccinated routinely
Novartis reports ‘clinically relevant’ survival data for Lutathera
The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours
NICE turns down GSK’s IV Benlysta for systemic lupus
The cost watchdog said uncertain trial evidence and cost-effectiveness estimates are behind the preliminary decision
Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
What’s next for patient advocacy?
Virtual event from OVID and the Patient Partnership Index is now open for registration
‘Indian’ variant of coronavirus now dominant strain in the UK
Officials warned that early evidence suggests there may be an increased risk of hospitalisation for Delta compared to the Alpha (Kent) strain
Novartis’ CAR T therapy Kymriah shows promise in follicular lymphoma
Kymriah led to responses for the majority of treated patients, with 66% achieving a complete response (CR)
